Search - tctmd.com

Displaying 1 - 18 of 18

Sort: Relevancy | Date

Presentation TCT 2025

TCT 497: Combined Assessment of Lipoprotein(a) and Non-Culprit Coronary LesionSeverity on Clinical Outcomes in Acute Coronary Syndrome

Presenter: Hirokazu Tanaka

October 28, 2025

Presentation TCT 2025

TCT 486: Lipoprotein(a) as a Predictor of Lesion Complexity in Patients undergoing Elective Percutaneous Coronary Intervention : Insights from an Asian single center cohort

Presenter: Melly Susanti

October 27, 2025

Presentation TCT 2025

TCT 485: Lipoprotein(a) and Long-Term Cardiovascular Events in Patients With Coronary Vasospasm

Presenter: Melly Susanti

October 27, 2025

Presentation TCT 2025

TCT 480: Imparied high-density lipoprotein functionality assessed by cholesterol uptake capacity might cause plaque vulnerability and unfavorable prognosis after percutaneous coronary intervention.

Presenter: Kotaro Higuchi

October 27, 2025

Presentation TCT 2025

TCT 475: Impact of Elevated Lipoprotein(a) on LDL Cholesterol Target Attainment Following PCI for Acute Coronary Syndrome Despite Intensive Triple Oral Lipid-Lowering Therapy: A Retrospective Cohort Study

Presenter: Kunal Mahajan

October 27, 2025

Presentation TCT 2025

TCT 1241: Atherogenic Lipoproteins and Intraplaque Lipid Burden: Evidence from NIRS-IVUS in Statin-Naive Patients

Presenter: Woohyeun Kim

October 26, 2025

News Daily News

PREVENT Risk Calculator’s Accuracy Varies by Healthcare System, Patient Factors

Michael O'Riordan

July 18, 2025

News Daily News

Majority of US Adults Have High Long-term Risk of CVD: NHANES

Michael O'Riordan

June 13, 2025

News Daily News

PREVENT Risk Calculator Works Well in Patients With High and Low Lp(a)

Michael O'Riordan

June 10, 2025

News Daily News

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Michael O'Riordan

June 04, 2025

News Opinion CV Team Dispatch

May 2025 Dispatch for the CV Team

L.A. McKeown

May 20, 2025

News Conference News EAS 2025

Back From the Brink: Obicetrapib Performs Well in BROADWAY, TANDEM

Yael L. Maxwell

May 08, 2025

News Daily News

Inclisiran Effective as Monotherapy for Lower-Risk Primary Prevention

Michael O'Riordan

May 07, 2025

News Daily News

Lp(a) Genetics Differ Between Populations but Have Similar Clinical Impact

Yael L. Maxwell

May 05, 2025

News Conference News ACC 2025

ALPACA: Injectable siRNA Agent Safe and Effective for Lowering Lp(a)

L.A. McKeown

April 10, 2025

News Opinion Editor's Corner ACC 2025

What’s Going to Be Hot at ACC 2025?

Michael O'Riordan

March 26, 2025

News Daily News

Olpasiran Cuts Lp(a) but Not Inflammatory Markers: OCEAN(a)-DOSE

Yael L. Maxwell

February 14, 2025

News Daily News

Higher Lp(a) Indicates Greater Chance of Stenosis on CCTA in Patients With Chest Pain

Yael L. Maxwell

January 13, 2025

Advertisement

TCT 497: Combined Assessment of Lipoprotein(a) and Non-Culprit Coronary LesionSeverity on Clinical Outcomes in Acute Coronary Syndrome

TCT 486: Lipoprotein(a) as a Predictor of Lesion Complexity in Patients undergoing Elective Percutaneous Coronary Intervention : Insights from an Asian single center cohort

TCT 485: Lipoprotein(a) and Long-Term Cardiovascular Events in Patients With Coronary Vasospasm

TCT 480: Imparied high-density lipoprotein functionality assessed by cholesterol uptake capacity might cause plaque vulnerability and unfavorable prognosis after percutaneous coronary intervention.

TCT 475: Impact of Elevated Lipoprotein(a) on LDL Cholesterol Target Attainment Following PCI for Acute Coronary Syndrome Despite Intensive Triple Oral Lipid-Lowering Therapy: A Retrospective Cohort Study

TCT 1241: Atherogenic Lipoproteins and Intraplaque Lipid Burden: Evidence from NIRS-IVUS in Statin-Naive Patients

PREVENT Risk Calculator’s Accuracy Varies by Healthcare System, Patient Factors

Majority of US Adults Have High Long-term Risk of CVD: NHANES

PREVENT Risk Calculator Works Well in Patients With High and Low Lp(a)

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

May 2025 Dispatch for the CV Team

Back From the Brink: Obicetrapib Performs Well in BROADWAY, TANDEM

Inclisiran Effective as Monotherapy for Lower-Risk Primary Prevention

Lp(a) Genetics Differ Between Populations but Have Similar Clinical Impact

ALPACA: Injectable siRNA Agent Safe and Effective for Lowering Lp(a)

What’s Going to Be Hot at ACC 2025?

Olpasiran Cuts Lp(a) but Not Inflammatory Markers: OCEAN(a)-DOSE

Higher Lp(a) Indicates Greater Chance of Stenosis on CCTA in Patients With Chest Pain

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content